Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05457855 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 51,533
- Enrollment target
NCT05457855: Completed study, sponsored by Brigham and Women's Hospital.
NCT05457855 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 51,533 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05457855 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 51,533 participants
- Enrollment target
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Interventions
- DRUG Fluticasone
- DRUG Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51,533 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT05457855 record still lists
NCT05457855 is an observational study that tracks outcomes without assigning an intervention. Its 51,533 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Fluticasone is the first listed.
NCT05457855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05457855 about?
NCT05457855 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT05457855?
This trial is currently completed. The enrollment target is 51,533 participants. The study started on 2022-02-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05457855?
The interventions under investigation include: Fluticasone (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT05457855?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI